Literature DB >> 21371516

Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.

Amy E Geddes1, Xu-Feng Huang, Kelly A Newell.   

Abstract

Schizophrenia is a debilitating neurodevelopmental psychiatric disorder. Both the N-methyl-D-aspartate receptor (NMDAR) and neuregulin1 (NRG1) are key molecules involved in normal brain development that have been linked to schizophrenia pathology and aetiology. The NR2 proteins are critical structural and functional subunits of the NMDAR and are developmentally and spatially regulated. Altered NR2 gene and protein expression has been found in human post-mortem schizophrenia brain tissue together with changes in NRG1 and its receptor ErbB4. The NR2 subunits and ErbB4 share a common anchoring domain on the postsynaptic density and therefore a disruption to either of these molecules may influence the functioning of the other. It has been shown that NRG1 signalling can affect NMDAR levels and function, particularly phosphorylation of the NR2 subunits. However little is known about the possible effects of NMDAR dysfunction on NRG1 signalling, which is important with regards to schizophrenia aetiology as numerous risk factors for the disorder can alter NMDAR functioning during early brain development. This review focuses on the role of the NMDA receptor subunits and NRG1 signalling in schizophrenia and proposes a mechanism by which a disruption to the NMDAR, particularly via altering the balance of NR2 subunits during early development, could influence NRG1 signalling.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371516     DOI: 10.1016/j.pnpbp.2011.02.017

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  20 in total

Review 1.  Molecular pathways: dysregulated glutamatergic signaling pathways in cancer.

Authors:  Todd D Prickett; Yardena Samuels
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

2.  mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

Authors:  Martin Engel; Peta Snikeris; Natalie Matosin; Kelly Anne Newell; Xu-Feng Huang; Elisabeth Frank
Journal:  Psychopharmacology (Berl)       Date:  2016-02-10       Impact factor: 4.530

3.  Role of N-Methyl-D-Aspartate Receptors in Action-Based Predictive Coding Deficits in Schizophrenia.

Authors:  Naomi S Kort; Judith M Ford; Brian J Roach; Handan Gunduz-Bruce; John H Krystal; Judith Jaeger; Robert M G Reinhart; Daniel H Mathalon
Journal:  Biol Psychiatry       Date:  2016-07-01       Impact factor: 13.382

4.  Probing NMDA receptor GluN2A and GluN2B subunit expression and distribution in cortical neurons.

Authors:  Rashna D Balsara; Ashley N Ferreira; Deborah L Donahue; Francis J Castellino; Patrick L Sheets
Journal:  Neuropharmacology       Date:  2014-01-15       Impact factor: 5.250

Review 5.  Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.

Authors:  Xiangyou Hu; Qingyuan Fan; Hailong Hou; Riqiang Yan
Journal:  J Neurochem       Date:  2015-11-13       Impact factor: 5.372

6.  Developmental Dysfunction of VIP Interneurons Impairs Cortical Circuits.

Authors:  Renata Batista-Brito; Martin Vinck; Katie A Ferguson; Jeremy T Chang; David Laubender; Gyorgy Lur; James M Mossner; Victoria G Hernandez; Charu Ramakrishnan; Karl Deisseroth; Michael J Higley; Jessica A Cardin
Journal:  Neuron       Date:  2017-08-16       Impact factor: 17.173

7.  Transcription factor Sp4 regulates expression of nervous wreck 2 to control NMDAR1 levels and dendrite patterning.

Authors:  Xinxin Sun; Raquel Pinacho; Gregory Saia; Diana Punko; J Javier Meana; Belén Ramos; Grace Gill
Journal:  Dev Neurobiol       Date:  2014-07-22       Impact factor: 3.964

Review 8.  Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.

Authors:  Tomás R Guilarte; Mark Opler; Mikhail Pletnikov
Journal:  Neurotoxicology       Date:  2011-12-09       Impact factor: 4.294

Review 9.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 10.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.